Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists

被引：0
|
作者：
Gianluigi Savarese
Felix Lindberg
Gerasimos Filippatos
Javed Butler
Stefan D. Anker
机构：
[1] Karolinska Institutet,Division of Cardiology, Department of Medicine
[2] Karolinska University Hospital,Heart and Vascular Theme
[3] University Hospital Attikon,Department of Cardiology
[4] National and Kapodistrian University of Athens,Department of Internal Medicine
[5] School of Medicine,Department of Cardiology (CVK) and Berlin Institute of Health Center for Regenerative Therapies, German Centre for Cardiovascular Research Partner Site Berlin
[6] Baylor Scott and White Research Institute,Institute of Heart Diseases
[7] University of Mississippi,undefined
[8] Charité Universitätsmedizin,undefined
[9] Wroclaw Medical University,undefined
来源：
Diabetologia | 2024年 / 67卷
关键词：
Eplerenone; Finerenone; Mineralocorticoid receptor; Mineralocorticoid receptor antagonists; Review; Spironolactone;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：246 / 262
页数：16
相关论文
共 50 条
  • [21] Mineralocorticoid receptor antagonists
    Hari Krishnan Parthasarathy
    Thomas M. MacDonald
    [J]. Current Hypertension Reports, 2007, 9 : 45 - 52
  • [22] The non-steroidal mineralocorticoid receptor antagonist finerenone prevents structural cardiac remodeling
    Lavall, D.
    Jacobs, N.
    Mahfoud, F.
    Kolkhof, P.
    Boehm, M.
    Laufs, U.
    [J]. EUROPEAN HEART JOURNAL, 2019, 40 : 3326 - 3326
  • [23] The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling
    Lavall, Daniel
    Jacobs, Nadine
    Mahfoud, Felix
    Kolkhof, Peter
    Boehm, Michael
    Laufs, Ulrich
    [J]. BIOCHEMICAL PHARMACOLOGY, 2019, 168 : 173 - 183
  • [24] Efficacy and safety of non-steroidal mineralocorticoid receptor antagonists for renal outcomes: A systematic review and meta-analysis
    Chen, Qi
    Liang, Yingnan
    Yan, Jiaxin
    Du, Yiran
    Li, Mengbi
    Chen, Zhenjie
    Zhou, Jingwei
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 195
  • [25] Non-steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease
    Al Dhaybi, Omar
    Bakris, George L.
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 : 69 - 76
  • [26] Aldosterone, Mineralocorticoid Receptor and the Metabolic Syndrome: Role of the Mineralocorticoid Receptor Antagonists
    Ronconi, Vanessa
    Turchi, Federica
    Appolloni, Gloria
    di Tizio, Valentina
    Boscaro, Marco
    Giacchetti, Gilberta
    [J]. CURRENT VASCULAR PHARMACOLOGY, 2012, 10 (02) : 238 - 246
  • [27] Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists
    Sueta, Daisuke
    Yamamoto, Eiichiro
    Tsujita, Kenichi
    [J]. CURRENT HYPERTENSION REPORTS, 2020, 22 (03)
  • [28] Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists
    Daisuke Sueta
    Eiichiro Yamamoto
    Kenichi Tsujita
    [J]. Current Hypertension Reports, 2020, 22
  • [29] Mineralocorticoid Receptor Antagonists in ESKD
    Agarwal, Adhish
    Cheung, Alfred K.
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2020, 15 (07): : 1047 - 1049
  • [30] Differentiation between emerging non-steroidal and established steroidal mineralocorticoid receptor antagonists: head-to-head comparisons of pharmacological and clinical characteristics
    Barrera-Chimal, Jonatan
    Kolkhof, Peter
    Lima-Posada, Ixchel
    Joachim, Alexandre
    Rossignol, Patrick
    Jaisser, Frederic
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2021, 30 (11) : 1141 - 1157
12345